1. Home
  2. FENG vs BCDA Comparison

FENG vs BCDA Comparison

Compare FENG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

N/A

Current Price

$1.40

Market Cap

18.1M

Sector

Industrials

ML Signal

N/A

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.91

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
BCDA
Founded
1998
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
15.7M
IPO Year
2011
2009

Fundamental Metrics

Financial Performance
Metric
FENG
BCDA
Price
$1.40
$0.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
26.6K
★ 153.0K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.39
$0.75
52 Week High
$2.43
$1.80

Technical Indicators

Market Signals
Indicator
FENG
BCDA
Relative Strength Index (RSI) 51.02 35.64
Support Level $1.42 $0.85
Resistance Level $1.52 $0.99
Average True Range (ATR) 0.03 0.06
MACD 0.00 -0.02
Stochastic Oscillator 54.55 20.88

Price Performance

Historical Comparison
FENG
BCDA

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: